Pharmacogenetic considerations in the treatment of psychiatric disorders

Abstract

Importance of the field: Despite continued efforts to optimize pharmacological treatment for individuals with psychiatric disorders, efficacy and tolerability of medication remains highly variable. In addition to clinical heterogeneity, diagnostic uncertainty, environmental, social factors, and genetic factors have been identified as playing an important role in the interindividual differences in therapeutic and toxic drug effects.

Areas covered in this review: This article describes recent developments in the field of psychiatric pharmacogenetics and focuses on antidepressant, antipsychotic, anticonvulsant, and mood-stabilizing drugs.

What the reader will gain: Recent findings from pharmacogenetic clinical trials are reviewed and clinical implications are discussed.

Take home message: Although current data are too sparse to allow the development of guidelines for using pharmacogenetic testing in routine clinical practice, the field of psychiatric pharmacogenetics is rapidly developing and identification of genetic biomarkers that predict therapeutic response and risk of side effects will ultimately help the practitioner to choose effective and safe treatment for patients suffering from psychiatric disorders.

Keywords::

• adverse events
• genetics
• personalized medicine
• pharmacogenomics
• pharmacology
• psychiatric disorders
• treatment response

Acknowledgements

This work was supported by the Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania.

Notes

This box summarises key points contained in the article.